Subjects Allocated to no Treatment in Trial GHLIQUID-1516 Will Subsequently Receive Growth Hormone for 4 Years.

This study has been completed.

Study NCT00184717 Information provided by Novo Nordisk

First Received: September 13, 2005 Last Updated: February 2, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	December 2009
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)